Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service hysterectomy, hysteroscopy & ablation cases in Delaware: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (238 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 7 | 485 | 18% |
| 2020 | 7 | 352 | 20% |
| 2021 | 6 | 408 | 25% |
| 2022 | 7 | 446 | 29% |
| 2023 | 9 | 474 | 32% |
| 2024 | 8 | 413 | 35% |
| 2025 from claims | – | 456 373–538 | 35% |
| 2026 forecast | – | 474 376–600 | 35% |
| 2027 forecast | – | 486 366–649 | 36% |
| 2028 forecast | – | 499 359–696 | 36% |
| 2029 forecast | – | 512 355–743 | 37% |
| 2030 forecast | – | 525 352–790 | 37% |
Laparoscopic/robotic hysterectomy, hysteroscopic resection, endometrial ablation. Professional codes (what the surgeon bills): CPT 58571, 58573, 58558, 58563, 58353, 58356, 58661, 58662.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Delaware; 6 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 3% inpatient hospital, 84% hospital outpatient, 5% surgery center, 8% office. The share outside the hospital has moved +5 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 83 | 6,179−1.2%/yr | −1.2%/yr | 3.1 | 27% | 7,510 in 2030+3.3%/yr |
| Texas | 48 | 4,404−1.1%/yr | −1.1%/yr | 2.3 | 16% | 5,010 in 2030+2.2%/yr |
| Maryland | 37 | 2,459−0.5%/yr | −0.5%/yr | 2.9 | 16% | 2,570 in 2030+0.7%/yr |
| North Carolina | 30 | 2,437−2.7%/yr | −2.7%/yr | 2.7 | 10% | 2,540 in 2030+0.7%/yr |
| Virginia | 31 | 2,422−2.5%/yr | −2.5%/yr | 2.5 | 15% | 2,670 in 2030+1.6%/yr |
| Georgia | 18 | 1,992−1.2%/yr | −1.2%/yr | 2.5 | 8% | 2,270 in 2030+2.2%/yr |
| Tennessee | 25 | 1,845−1.1%/yr | −1.1%/yr | 2.9 | 11% | 1,830 in 2030−0.1%/yr |
| South Carolina | 15 | 1,349−1.6%/yr | −1.6%/yr | 2.1 | 7% | 1,610 in 2030+3%/yr |
| Kentucky | 13 | 1,062−5.7%/yr | −5.7%/yr | 2.5 | 9% | 910 in 2030−2.6%/yr |
| Oklahoma | 7 | 1,015−0.3%/yr | −0.3%/yr | 2.3 | 0% | 1,190 in 2030+2.7%/yr |
| Alabama | 8 | 873−6.8%/yr | −6.8%/yr | 2.2 | 13% | 830 in 2030−0.8%/yr |
| Arkansas | 6 | 776−1.9%/yr | −1.9%/yr | 2.2 | 14% | 750 in 2030−0.6%/yr |
| Louisiana | 4 | 741−6.5%/yr | −6.5%/yr | 2.0 | 14% | 660 in 2030−2%/yr |
| Mississippi | 8 | 567−7.3%/yr | −7.3%/yr | 1.6 | 9% | 560 in 2030−0.3%/yr |
| West Virginia | 4 | 566−4.1%/yr | −4.1%/yr | 3.0 | 5% | 510 in 2030−1.7%/yr |
| District of Columbia | 4 | 298+6.3%/yr | +6.3%/yr | 5.1 | 31% | 440 in 2030+6.9%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 19 | 813−2.6%/yr | −2.6%/yr | 4.80.9× | 31% | 870 in 2030+1.1%/yr |
| BPH procedures | 11 | 724−5%/yr | −5%/yr | 4.20.8× | 45% | 780 in 2030+1.4%/yr |
| Incontinence, prolapse & sacral neuromodulation | 3 | 291−0.5%/yr | −0.5%/yr | 1.70.6× | 0% | 390 in 2030+5.2%/yr |
Hysterectomy, hysteroscopy & ablation in every state, and its device makers · Every procedure market in Delaware · Every state · Compare with Florida
Acessa Health leads with 80% of company spending on these surgeons in 2025, +9 pts on 2024.
In 2025, 3 companies reported engagement with Delaware’s surgeons worth $9,960 in consulting, speaking, meals and travel tied to these products, about $1,245 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.